These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33233956)

  • 21. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
    Chen YL; Wang GX; Lin BA; Huang JS
    Cell Biol Int; 2020 May; 44(5):1224-1236. PubMed ID: 32068322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
    Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
    Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
    [No Abstract]   [Full Text] [Related]  

  • 25. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.
    Yaghoubi N; Soltani A; Ghazvini K; Hassanian SM; Hashemy SI
    Biomed Pharmacother; 2019 Feb; 110():312-318. PubMed ID: 30522017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Precision USPIO-PEG-SLe
    Li T; Guo L; Li J; Mu X; Liu L; Song S; Luo N; Zhang Q; Zheng B; Jin G
    Int J Nanomedicine; 2024; 19():1249-1272. PubMed ID: 38348177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.
    Lau J; Cheung J; Navarro A; Lianoglou S; Haley B; Totpal K; Sanders L; Koeppen H; Caplazi P; McBride J; Chiu H; Hong R; Grogan J; Javinal V; Yauch R; Irving B; Belvin M; Mellman I; Kim JM; Schmidt M
    Nat Commun; 2017 Feb; 8():14572. PubMed ID: 28220772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer.
    Sun Z; Zhang Y; Cao D; Wang X; Yan X; Li H; Huang L; Qu X; Kong C; Qin H; Wang M; Xu W; Liang L
    Drug Deliv; 2018 Nov; 25(1):1746-1755. PubMed ID: 30394118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A tumor microenvironment responsive biodegradable CaCO
    Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D
    Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment.
    Lv J; Jia Y; Li J; Kuai W; Li Y; Guo F; Xu X; Zhao Z; Lv J; Li Z
    Cell Death Dis; 2019 May; 10(6):415. PubMed ID: 31138779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma.
    Hacking S; Vitkovski T; Jain S; Jin C; Chavarria H; Wu D; Nasim M
    Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):201-208. PubMed ID: 32842025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy.
    Liu C; Zhou F; Yan Z; Shen L; Zhang X; He F; Wang H; Lu X; Yu K; Zhao Y; Zhu D
    Br J Pharmacol; 2021 Jul; 178(13):2651-2670. PubMed ID: 33768523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.
    Chang K; Svabek C; Vazquez-Guillamet C; Sato B; Rasche D; Wilson S; Robbins P; Ulbrandt N; Suzich J; Green J; Patera AC; Blair W; Krishnan S; Hotchkiss R
    Crit Care; 2014 Jan; 18(1):R3. PubMed ID: 24387680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5.
    Li Z; Zhou J; Zhang J; Li S; Wang H; Du J
    Int J Cancer; 2019 Oct; 145(7):1946-1957. PubMed ID: 30873585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
    Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
    Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice.
    Yassin M; Sadowska Z; Djurhuus D; Nielsen B; Tougaard P; Olsen J; Pedersen AE
    Immunology; 2019 Sep; 158(1):35-46. PubMed ID: 31429085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.